Thank you to our sponsors!
2
Virtual ASCO 2021 Total ASCO abstracts for 2021 = 4,782 Myeloma Abstracts = 282 Oral = 26 Poster Discussion = 32 Poster Session = 106 Publication Only = 118 3
Abstract #8005
https://www.myeloma.org/videos/ciltacabtagene-autoleucel-bcma-directed-cart-therapy-relapsed-refractory-multiple-myeloma-cartitude1
4
CARTITUDE-1 Update • • • • •
Median follow-up – 18 months Overall response rate = 98% (!) sCR = 80% Response duration = 66% at 18 months Some newer concerns about delayed toxicities and how to mitigate. 5
Abstract #8007
https://www.myeloma.org/videos/updated-phase-1-teclistamab-trial-results-relasped-refractory-multiple-myeloma
6
Teclistamab Update • 40 patients • Response rate = 65% • Of responders: • VGPR = 58% • CR/ sCR = 30% • Toxicities acceptable/ manageable for this bispecific 7
Abstract #8006
https://www.myeloma.org/videos/efficacy-safety-elranatamab-bcma-cd3-bispecific-antibody-patients-relapsed-or-refractory
8
What’s next for CAR T? • Rollout of approved products • Earlier use • Next generation CARs 9
Where will bi-specifics fit in? • Ongoing IV/ SC • Course of therapy – 6 months? • Toxicity concerns persist? 10
Abstract #8004
https://www.myeloma.org/videos/daratumumab-maintenance-or-observation-after-treatment-vtd-asct-patients-cassiopeia
11
CASSIOPEIA Update Key Point • Dara maintenance – no added benefit with Dara VTd induction/ consolidation • Does this change thinking about Dara maintenance? 12
Abstract #8000
https://www.myeloma.org/videos/upfront-autologous-stem-cell-transplantation-versus-KCd-k-maintenance-cardamon-trial
13
KCd +/- ASCT and K maintenance • KCd and ASCT consolidation equivalent • High risk patients continue to do more poorly
14
Abstract #10507
Second primary malignancies (SPM) in African American (AA) and white patients with multiple myeloma in the National Veterans Affairs (VA) healthcare system. https://meetinglibrary.asco.org/record/197653/abstract
Nikhil Munshi Dana-Farber Cancer Institute Boston, MA, USA
15
Key questions about induction • Will Quads take over? • Dara or Isa with V/KRd or V/KTd
• Is frontline transplant now optional? OR • Based upon MRD status? • Is SPM occurrence important? 16
Key questions about induction • Will new immune therapies become consolidation of choice?
17
EHA Late Breaking Abstract
https://www.myeloma.org/videos/overall-survival-results-daratumumab-lenalidomide-dexamethasone-transplant-ineligible-MAIA
18
Updated PFS 60-month PFS rate
% surviving without progression
100 80 52.5%
60
D-Rd: median, NR 28.7%
40
Rd: median, 34.4 months 20
HR, 0.53; 95% CI, 0.43-0.66; P <0.0001
0
0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60 63 66 69 Months No. at risk Rd 369 333 307 280 255 237 220 205 196 179 172 155 146 133 123 113 105 94 63 36 12 4 D-Rd 368 347 335 320 309 300 290 276 266 256 246 237 232 222 210 199 195 170 123 87 51 17
2 5
0 0
• D-Rd continued to demonstrate a significant PFS benefit, with median PFS not reached with D-Rd • These data provide a new PFS benchmark in patients with NDMM who are transplant ineligible NR, not reached; CI, confidence interval.
OS 60-month OS rate
100
% surviving
80
66.3% D-Rd: median, NR
53.1%
60
Rd: median, NR 40
20
HR, 0.68; 95% CI, 0.53-0.86; P = 0.0013
0 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60 63 66 69 72 Months No. at risk Rd 369 351 343 336 324 317 308 300 294 281 270 258 251 241 232 223 213 183 134 85 42 14 5 D-Rd 368 350 346 344 338 334 328 316 305 302 297 286 280 273 266 255 249 228 170 118 63 22 6
1 1
0 0
D-Rd demonstrated a significant benefit in OS, with a 32% reduction in the risk of death, in patients with NDMM who are transplant ineligible
Panel Discussion 21
Abstract #8009
MASS-FIX versus standard methods to predict for PFS and OS among multiple myeloma patients participating on the STAMINA trial. https://meetinglibrary.asco.org/record/196625/abstract
Angela Dispenzieri Mayo Clinic Rochester, MN, USA
22
MASS-FIX Testing in STAMINA Trial • MASS-FIX excellent independent predictor of PFS and OS
• Compared with MRD Testing with NGF * Promising use of simple blood testing 23
Abstract #8010
Analysis of minimal residual disease in bone marrow by NGF and in peripheral blood by mass spectrometry in newly diagnosed multiple myeloma patients enrolled in the GEM2012MENOS65 clinical trial.
Noemi Puig University of Salamanca Salamanca, Spain
https://meetinglibrary.asco.org/record/195522/abstract
24
Mass spectrometry in GEM (Spanish) Trial • Mass Spec and MRD by NGF found to be complementary in assessing outcomes
• Patterns of NGF +/- and Mass Spec +/being further studied 25
Abstract #8001
https://www.myeloma.org/videos/depth-response-minimal-residual-disease-status-ultra-high-risk-multiple-myeloma-muknine-study
26
Key questions about Mass Spec • Can it provide good MRD monitoring? • How easy will it be to switch from SPEP/ IFE? • Relapse • Early disease 27
Abstract #8012
https://www.myeloma.org/videos/prospective-comparison-whole-body-mri-fdg-pet-ct-detection-multiple-myeloma-correlation
28
Key questions about imaging • Is WBLDCT (Whole Body Low Dose CT) the standard?
• What about PET/CT versus MRI?
29
Abstract #8019
Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study. https://meetinglibrary.asco.org/record/195458/abstract
Thierry Facon Université of Lille, CHU Lille, Service des Maladies du Sang, Lille, France
30
Selinexor in Elderly: Update • Patients over age 65 years • Excellent results with selinexor + Vd (BOSTON regimen) re: efficacy/ toxicity
• Both PFS and OS improved 31
Panel Discussion 32
Key questions from IMWG Summit • Several items already discussed • Additional points: • Diagnosis/ treatment for HR/ ultra HR SMM (2/20/20 system) • Immune therapy registry and virtual biobank 33
Key questions from IMWG Summit • Additional points: • Role of new MoAbs and new agents (ex. CelMods) • COVID-19 vaccination
34
Panel Discussion 35
Thank you to our sponsors!
36